Share on Facebook Share on Twitter Email
Answers.com

Tegaserod

 
Drug Info:

Tegaserod

Brand names: Zelnorm®

Chemical formula:



Tegaserod Oral tablet

What is this medicine?

TEGASEROD (te GAS a rod) is used to treat women who have irritable bowel syndrome (IBS) with constipation as their main problem. It may also be used for relief of chronic constipation in patients (men and women) less than 65 years of age.
 
NOTE: This drug is no longer available in the United States. Patients currently taking Tegaserod should contact their prescriber about stopping this medicine and finding alternative therapies. If you have questions about the discontinuation of Zelnorm you may call 1-888-669-6682.
 
This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.

What should I tell my health care provider before I take this medicine?

They need to know if you have any of these conditions:
•anxiety
•depression
•diabetes
•heart disease
•high blood pressure
•high cholesterol
•gallbladder disease
•kidney or liver disease
•now have diarrhea or have diarrhea often
•previous heart attack
•previous stroke
•rectal bleeding
•stomach or intestinal disease, including bowel obstruction or abdominal adhesions
•suicidal thoughts, plans, or attempt
•an unusual or allergic reaction to tegaserod, other medicines, foods, dyes, or preservatives
•pregnant or trying to get pregnant
•breast-feeding

How should I use this medicine?

Take this medicine by mouth with a glass of water. Take it on an empty stomach shortly before you eat a meal. Follow the directions on the prescription label. Take your doses at regular intervals. Do not take your medicine more often than directed.

Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.

Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.
NOTE: This medicine is only for you. Do not share this medicine with others.

What may interact with this medicine?

•medicines for bowel problems or bladder incontinence (these can cause constipation)

This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.

What should I watch for while using this medicine?

Diarrhea is a common side effect that usually happens in the first week of starting the medicine. This will usually last only a few days and will not come back. You should not start taking this medicine if you already have diarrhea or have diarrhea most of the time. Severe or prolonged diarrhea can lead to dehydration, a lack of fluids within your body. If you experience severe cramping, stomach pain, lightheadedness, dizziness or fainting accompanied by diarrhea, tell your doctor or health care professional immediately.

If you get new or worsening stomach pain with or without blood in your stools, call your doctor or health care professional right away.

This medicine may not work for all patients. It may take several weeks for you notice any relief from your symptoms. If this medicine is stopped, it is likely that that your symptoms will return within 1 to 2 weeks.

Your diet and stress levels may affect your course of therapy. If you eat something that seems make constipation worse or if you have significant levels of stress in your life, be sure to discuss this with your health care professional.

What side effects may I notice from receiving this medicine?

Side effects that you should report to your doctor or health professional as soon as possible:
•diarrhea accompanied by severe stomach cramps with or without rectal bleeding, other stomach pain or dizziness
•new or worsening stomach pain
•sudden onset of chest pain
•worsening or prolonged diarrhea

Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
•gas
•headache
•heartburn
•mild dizziness
•nausea or vomiting

This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Where should I keep my medicine?

Keep out of the reach of children.

Store at room temperature between 15 and 30 degrees C (59 and 86 degree F). Protect from heat and moisture. Throw away any unused medicine after the expiration date.

Last updated: 7/1/2002

Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.

Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
Tegaserod
Systematic (IUPAC) name
(2E)-2-[(5-Methoxy-1H-indol-3-yl)methylene]-N-pentylhydrazinecarboximidamide
Clinical data
AHFS/Drugs.com monograph
Pregnancy cat. B3(AU) B(US)
Legal status Withdrawn
Routes Oral
Pharmacokinetic data
Bioavailability 10%
Protein binding 98%
Metabolism Gastric and hepatic
Half-life 11 ± 5 hours
Excretion Fecal and renal
Identifiers
CAS number 189188-57-6 N
ATC code A03AE02
PubChem CID 5362436
DrugBank DB01079
ChemSpider 10609889 YesY
UNII 458VC51857 YesY
KEGG D02730 YesY
ChEMBL CHEMBL76370 YesY
Chemical data
Formula C16H23N5O 
Mol. mass 301.39 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the name Zelnorm for the management of irritable bowel syndrome and constipation.[1] Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation.[2]

Mechanism of action

The drug functions as a motility stimulant, achieving its desired therapeutic effects through activation of the 5-HT4 receptors of the enteric nervous system in the gastrointestinal tract. It also stimulates gastrointestinal motility and the peristaltic reflex, and allegedly reduces abdominal pain.[3] Additionally, tegaserod is a 5-HT2B receptor antagonist.[4]

Withdrawal from market

On March 30, 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves.[5] The FDA alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke. An analysis of data collected on over 18,000 patients demonstrated adverse cardiovascular events in 13 of 11,614 patients treated with Zelnorm (a rate of 0.11%) as compared with 1 of 7,031 patients treated with placebo (a rate of 0.01%). Novartis alleges all of the affected patients had preexisting cardiovascular disease or risk factors for such, and further alleges that no causal relationship between tegaserod use and cardiovascular events has been demonstrated.[6] On the same day as the FDA announcement, Novartis Pharmaceuticals Canada announced that it was suspending marketing and sales of the drug in Canada in response to a request from Health Canada.[7] Some manufacturers in India, such as Cipla and Torrent Pharmaceuticals Ltd., seem to still have generic tegaserod available in their listings[8] and some online merchants may be selling it, despite the drug being banned in India. In a large cohort study based on a US health insurance database, no increase in the risk of cardiovascular events were found under tegaserod treatment.[9]

References

  1. ^ "New Data for Zelnorm". http://www.pharma.us.novartis.com/newsroom/pressReleases/releaseDetail.jsp?PRID=2004. Retrieved March 30, 2007. 
  2. ^ "FDA approves first treatment for women with irritable-bowel syndrome". Archived from the original on February 5, 2007. http://web.archive.org/web/20070205163603/http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01160.html. Retrieved March 30, 2007. 
  3. ^ Rossi, S. (2004). Australian Medicines Handbook. Adelaide: Health Communication Network. ISBN 0-9578521-4-2. 
  4. ^ Beattie DT, Smith JA, Marquess D, et al. (November 2004). "The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo". Br. J. Pharmacol. 143 (5): 549–60. doi:10.1038/sj.bjp.0705929. PMC 1575425. PMID 15466450. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1575425. 
  5. ^ "FDA Announces Discontinued Marketing of GI Drug, Zelnorm, for Safety Reasons". FDA Press Release. 30 March 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108879.htm. 
  6. ^ "Zelnorm" (PDF). Novartis. Archived from the original on 2007-04-10. http://web.archive.org/web/20070410024119/http://www.zelnorm.com/Zelnrom_PR_US_330_Final_12_1007.pdf. Retrieved 2007-03-30. 
  7. ^ "Novartis suspends Canadian marketing and sales of Zelnorm in response to request from Health Canada". http://www.newswire.ca/en/releases/archive/March2007/30/c9000.html. Retrieved 2007-03-30. 
  8. ^ Cipla - Product List
  9. ^ "Tegaserod and the Risk of Cardiovascular Ischemic Events: An Observational Cohort Study.". http://www.ncbi.nlm.nih.gov/pubmed/20200325. Retrieved March 3, 2010. 

 
 
Related topics:
Tegaserod Oral tablet
Tegaserod, Tableta oral
Atropine tablets or soluble tablets

Post a question - any question - to the WikiAnswers community:

 

Copyrights:

Drug Info. Gold Standard. Copyright © 2008 by Gold Standard. All rights reserved.  Read more
Wikipedia on Answers.com. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Tegaserod Read more

Follow us
Facebook Twitter
YouTube